BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hindorf U, Johansson M, Eriksson A, Kvifors E, Almer SH. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009;29:654-661. [PMID: 19183142 DOI: 10.1111/j.1365-2036.2008.03925.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Ansari A, Patel N, Sanderson J, O’Donohue J, Duley JA, Florin TH. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:640-647. [PMID: 20015102 DOI: 10.1111/j.1365-2036.2009.04221.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 91] [Article Influence: 8.8] [Reference Citation Analysis]
2 Dewit O, Starkel P, Roblin X. Thiopurine metabolism monitoring: implications in inflammatory bowel diseases. Eur J Clin Invest. 2010;40:1037-1047. [PMID: 20629710 DOI: 10.1111/j.1365-2362.2010.02346.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
3 Hindorf U, Andersson P. How are thiopurines used and monitored by Swedish gastroenterologists when treating patients with inflammatory bowel disease? Scandinavian Journal of Gastroenterology 2011;46:1215-21. [DOI: 10.3109/00365521.2011.603162] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
4 Loit E, Tricco AC, Tsouros S, Sears M, Ansari MT, Booth RA. Pre-analytic and analytic sources of variations in thiopurine methyltransferase activity measurement in patients prescribed thiopurine-based drugs: A systematic review. Clin Biochem. 2011;44:751-757. [PMID: 21402061 DOI: 10.1016/j.clinbiochem.2011.03.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
5 Losurdo G, Brescia IV, Lillo C, Mezzapesa M, Barone M, Principi M, Ierardi E, Di Leo A, Rendina M. Liver involvement in inflammatory bowel disease: What should the clinician know? World J Hepatol 2021; 13(11): 1534-1551 [DOI: 10.4254/wjh.v13.i11.1534] [Reference Citation Analysis]
6 Jagt JZ, Pothof CD, Buiter HJC, van Limbergen JE, van Wijk MP, Benninga MA, de Boer NKH, de Meij TGJ. Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study. Dig Dis Sci 2021. [PMID: 33532972 DOI: 10.1007/s10620-021-06836-3] [Reference Citation Analysis]
7 Gisbert JP, Chaparro M, Gomollón F. Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease. World J Gastroenterol 2011; 17(30): 3467-3478 [PMID: 21941413 DOI: 10.3748/wjg.v17.i30.3467] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
8 Macaluso FS, Renna S, Maida M, Dimarco M, Sapienza C, Affronti M, Orlando E, Rizzuto G, Orlando R, Ventimiglia M, Cottone M, Orlando A. Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience. Scandinavian Journal of Gastroenterology 2017. [DOI: 10.1080/00365521.2017.1333626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
9 Ferrante M, Karmiris K, Newnham E, Siffledeen J, Zelinkova Z, van Assche G, Lakatos PL, Panés J, Sturm A, Travis S, van der Woude CJ, Reinisch W, Colombel J, Panaccione R. Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme. Journal of Crohn's and Colitis 2012;6:116-31. [DOI: 10.1016/j.crohns.2011.09.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
10 Ha C, Dassopoulos T. Thiopurine therapy in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2010;4:575-588. [PMID: 20932143 DOI: 10.1586/egh.10.59] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
11 Andrejic J, Rojas-balcazar J, Dennis M, Berkelhammer C. Azathioprine-induced hypersensitivity hepatitis: Tolerance to 6-mercaptopurine: . Inflammatory Bowel Diseases 2010;16:1828-9. [DOI: 10.1002/ibd.21240] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Beswick L, Friedman AB, Sparrow MP. The role of thiopurine metabolite monitoring in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2014;8:383-92. [PMID: 24684593 DOI: 10.1586/17474124.2014.894878] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
13 van Asseldonk DP, Sanderson J, de Boer NK, Sparrow MP, Lémann M, Ansari A, Almer SH, Florin TH, Gearry RB, Mulder CJ. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease--proceedings of the first Thiopurine Task Force meeting. Dig Liver Dis. 2011;43:270-276. [PMID: 20934926 DOI: 10.1016/j.dld.2010.09.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
14 Goldberg R, Irving PM. Toxicity and response to thiopurines in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2015;9:891-900. [PMID: 25915575 DOI: 10.1586/17474124.2015.1039987] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
15 Miheller P, Lakatos PL. Thiopurines in Crohn’s disease, is there something new? Expert Opin Drug Metab Toxicol. 2010;6:1505-1514. [PMID: 20919963 DOI: 10.1517/17425255.2010.525505] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
16 Hindorf U, Jahed K, Bergquist A, Verbaan H, Prytz H, Wallerstedt S, Werner M, Olsson R, Björnsson E, Peterson C, Almer SH. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. J Hepatol 2010;52:106-11. [PMID: 19906459 DOI: 10.1016/j.jhep.2009.10.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
17 Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. Autoimmmune hepatitis. Cell Mol Immunol 2021. [PMID: 34580437 DOI: 10.1038/s41423-021-00768-8] [Reference Citation Analysis]
18 Taylor KM, Irving PM. Optimization of conventional therapy in patients with IBD. Nat Rev Gastroenterol Hepatol. 2011;8:646-656. [PMID: 21970871 DOI: 10.1038/nrgastro.2011.172] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
19 Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther. 2011;5:185-210. [PMID: 21552489 DOI: 10.2147/dddt.s11290] [Cited by in Crossref: 137] [Cited by in F6Publishing: 76] [Article Influence: 13.7] [Reference Citation Analysis]
20 Bermejo F, López-Sanromán A, Algaba A, Van-Domselaar M, Gisbert JP, García-Garzón S, Garrido E, Piqueras B, De La Poza G, Guerra I. Mercaptopurine rescue after azathioprine-induced liver injury in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:120-124. [PMID: 19709096 DOI: 10.1111/j.1365-2036.2009.04132.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
21 Landerholm K, Kalman D, Wallon C, Myrelid P. Immunomodulators: Friends or Enemies in Surgery for Crohn’s Disease? CDT 2019;20:1384-98. [DOI: 10.2174/1389450120666190617163919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Hoentjen F, Sakuraba A, Hanauer S. Update on the Management of Ulcerative Colitis. Curr Gastroenterol Rep 2011;13:475-85. [DOI: 10.1007/s11894-011-0216-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
23 Smith MA, Blaker P, Marinaki AM, Anderson SH, Irving PM, Sanderson JD. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohns Colitis. 2012;6:905-912. [PMID: 22386736 DOI: 10.1016/j.crohns.2012.02.007] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 8.3] [Reference Citation Analysis]
24 Renna S, Cottone M, Orlando A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol 2014; 20(29): 9675-9690 [PMID: 25110407 DOI: 10.3748/wjg.v20.i29.9675] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 38] [Article Influence: 6.4] [Reference Citation Analysis]
25 Meijer B, Mulder CJ, van Bodegraven AA, de Boer NKH. How I treat my inflammatory bowel disease-patients with thiopurines? World J Gastrointest Pharmacol Ther 2016; 7(4): 524-530 [PMID: 27867685 DOI: 10.4292/wjgpt.v7.i4.524] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
26 Kennedy NA, Lees CW. Letter: Azathioprine-induced pancreatitis and subsequent tolerance of mercaptopurine--authors' reply. Aliment Pharmacol Ther 2014;39:440-1. [PMID: 24447316 DOI: 10.1111/apt.12602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
27 Renna S, Orlando A, Cottone M. Comparing medical treatments for Crohn's disease. J Comp Eff Res 2013;2:135-49. [PMID: 24236556 DOI: 10.2217/cer.13.2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 van Hoeve K, Vermeire S. Thiopurines in Pediatric Inflammatory Bowel Disease: Current and Future Place. Paediatr Drugs 2020;22:449-61. [PMID: 32797366 DOI: 10.1007/s40272-020-00411-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Chouchana L, Narjoz C, Beaune P, Loriot M, Roblin X. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease: Review: pharmacogenetics of thiopurines in IBD. Alimentary Pharmacology & Therapeutics 2012;35:15-36. [DOI: 10.1111/j.1365-2036.2011.04905.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 100] [Article Influence: 11.1] [Reference Citation Analysis]
30 Friedman AB, Sparrow MP, Gibson PR. The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders. Int J Rheum Dis 2014;17:132-41. [PMID: 24618304 DOI: 10.1111/1756-185X.12204] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
31 Kuriyama M, Kato J, Suzuki H, Akita M, Hiraoka S, Okada H, Yamamoto K. TOLERABILITY AND USEFULNESS OF MERCAPTOPURINE IN AZATHIOPRINE-INTOLERANT JAPANESE PATIENTS WITH ULCERATIVE COLITIS: TOLERABILITY OF 6-MP IN UC PATIENTS. Digestive Endoscopy 2010;22:289-96. [DOI: 10.1111/j.1443-1661.2010.01009.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
32 Tran-Minh ML, Sousa P, Maillet M, Allez M, Gornet JM. Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease. World J Hepatol 2017; 9(13): 613-626 [PMID: 28539989 DOI: 10.4254/wjh.v9.i13.613] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
33 Beswick L, Hair CS, Dowling D. Letter: successful mercaptopurine therapy after azathioprine-related pancreatitis in patients with IBD. Aliment Pharmacol Ther 2013;37:162-162. [DOI: 10.1111/apt.12097] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
34 Pittet V, Froehlich F, Maillard MH, Mottet C, Gonvers JJ, Felley C, Vader JP, Burnand B, Michetti P, Schoepfer A. When do we dare to stop biological or immunomodulatory therapy for Crohn’s disease? Results of a multidisciplinary European expert panel. J Crohns Colitis. 2013;7:820-826. [PMID: 23664620 DOI: 10.1016/j.crohns.2013.04.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
35 Dart RJ, Irving PM. Optimising use of thiopurines in inflammatory bowel disease. Expert Review of Clinical Immunology 2017;13:877-88. [DOI: 10.1080/1744666x.2017.1351298] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
36 Raj LS, Hawthorne AB. Optimising use of thiopurines in inflammatory bowel disease. Frontline Gastroenterol 2010;1:44-51. [PMID: 28839543 DOI: 10.1136/fg.2009.000174] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
37 Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). J Dig Dis 2021;22:298-317. [PMID: 33905603 DOI: 10.1111/1751-2980.12994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Taylor KM, Ward MG, Blaker PA, Sparrow MP. Is there a role for thioguanine therapy in IBD in 2017 and beyond? Expert Review of Gastroenterology & Hepatology 2017;11:473-86. [DOI: 10.1080/17474124.2017.1294062] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
39 Meijer B, Kreijne JE, van Moorsel SAW, Derijks LJJ, Bouma G, Mulder CJJ, Wong DR, van der Woude CJ, van Bodegraven AA, de Boer NKH. 6-methylmercaptopurine-induced leukocytopenia during thiopurine therapy in inflammatory bowel disease patients. J Gastroenterol Hepatol 2017;32:1183-90. [PMID: 27859568 DOI: 10.1111/jgh.13656] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
40 Lammert C, Loy VM, Oshima K, Gawrieh S. Management of Difficult Cases of Autoimmune Hepatitis. Curr Gastroenterol Rep. 2016;18:9. [PMID: 26780632 DOI: 10.1007/s11894-015-0484-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
41 Ramos LR, Sachar DB, DiMaio CJ, Colombel JF, Torres J. Inflammatory bowel disease and pancreatitis: a review. J Crohns Colitis. 2016;10:95-104. [PMID: 26351384 DOI: 10.1093/ecco-jcc/jjv153] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
42 Frei P, Biedermann L, Nielsen OH, Rogler G. Use of thiopurines in inflammatory bowel disease. World J Gastroenterol 2013; 19(7): 1040-1048 [PMID: 23467510 DOI: 10.3748/wjg.v19.i7.1040] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
43 De Boer NK, Van Bodegraven AA. Get the Best Out of Thiopurine Therapy. Gastroenterology 2014;146:865. [DOI: 10.1053/j.gastro.2013.08.062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
44 Meggitt SJ, Anstey AV, Mohd Mustapa MF, Reynolds NJ, Wakelin S. British Association of Dermatologists’ guidelines for the safe and effective prescribing of azathioprine 2011. Br J Dermatol. 2011;165:711-734. [PMID: 21950502 DOI: 10.1111/j.1365-2133.2011.10575.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 53] [Article Influence: 8.4] [Reference Citation Analysis]
45 Vikingsson S, Andersson D, Almer S, Peterson C, Hindorf U. Novel assay to improve therapeutic drug monitoring of thiopurines in inflammatory bowel disease. J Crohns Colitis 2014;8:1702-9. [PMID: 25239576 DOI: 10.1016/j.crohns.2014.08.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
46 Cottone M, Renna S, Orlando A, Mocciaro F. Medical management of Crohn's disease. Expert Opin Pharmacother. 2011;12:2505-2525. [PMID: 21988215 DOI: 10.1517/14656566.2011.609556] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
47 Kennedy NA, Rhatigan E, Arnott ID, Noble CL, Shand AG, Satsangi J, Lees CW. A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis. Aliment Pharmacol Ther. 2013;38:1255-1266. [PMID: 24117596 DOI: 10.1111/apt.12511] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
48 Cotter TG, Kamboj AK, Hicks SB, Tremaine WJ, Loftus EV, Pardi DS. Immune modulator therapy for microscopic colitis in a case series of 73 patients. Aliment Pharmacol Ther 2017;46:169-74. [PMID: 28488312 DOI: 10.1111/apt.14133] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
49 Chaparro M, Ordás I, Cabré E, Garcia-sanchez V, Bastida G, Peñalva M, Gomollón F, García-planella E, Merino O, Gutiérrez A, Esteve M, Márquez L, Garcia-sepulcre M, Hinojosa J, Vera I, Muñoz F, Mendoza JL, Cabriada JL, Montoro MA, Barreiro-de Acosta M, Ceña G, Saro C, Aldeguer X, Barrio J, Maté J, Gisbert JP. Safety of Thiopurine Therapy in Inflammatory Bowel Disease: Long-term Follow-up Study of 3931 Patients. Inflammatory Bowel Diseases 2013;19:1404-10. [DOI: 10.1097/mib.0b013e318281f28f] [Cited by in Crossref: 178] [Cited by in F6Publishing: 62] [Article Influence: 22.3] [Reference Citation Analysis]
50 Meijer B, Bouma G, de Boer NK. Optimize Thiopurine Therapy in Autoimmune Hepatitis. Clin Gastroenterol Hepatol. 2016;14:1062-1063. [PMID: 26872401 DOI: 10.1016/j.cgh.2016.02.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
51 Vergani D, Terziroli Beretta-Piccoli B, Mieli-Vergani G. A reasoned approach to the treatment of autoimmune hepatitis. Dig Liver Dis 2021:S1590-8658(21)00307-8. [PMID: 34162505 DOI: 10.1016/j.dld.2021.05.033] [Reference Citation Analysis]
52 Almer S. Novel strategies in the thiopurine treatment of inflammatory bowel disease. Nucleosides Nucleotides Nucleic Acids 2010;29:267-77. [PMID: 20544506 DOI: 10.1080/15257771003729559] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
53 Nielsen OH, Bjerrum JT, Herfarth H, Rogler G. Recent advances using immunomodulators for inflammatory bowel disease. J Clin Pharmacol. 2013;53:575-588. [PMID: 23408468 DOI: 10.1002/jcph.2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
54 Münch A, Fernandez-Banares F, Munck LK. Azathioprine and mercaptopurine in the management of patients with chronic, active microscopic colitis. Aliment Pharmacol Ther. 2013;37:795-798. [PMID: 23432370 DOI: 10.1111/apt.12261] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
55 Meijer B, Seinen ML, Leijte NN, Mulder CJ, van Bodegraven AA, de Boer NK. Clinical Value of Mercaptopurine After Failing Azathioprine Therapy in Patients With Inflammatory Bowel Disease. Ther Drug Monit. 2016;38:463-470. [PMID: 27158876 DOI: 10.1097/ftd.0000000000000312] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
56 Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments. World J Gastroenterol 2017; 23(33): 6030-6048 [PMID: 28970719 DOI: 10.3748/wjg.v23.i33.6030] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 39] [Article Influence: 12.3] [Reference Citation Analysis]
57 Lakatos PL, Kiss LS. Current status of thiopurine analogues in the treatment in Crohn's disease. World J Gastroenterol 2011; 17(39): 4372-4381 [PMID: 22110262 DOI: 10.3748/wjg.v17.i39.4372] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
58 Bermejo F, Aguas M, Chaparro M, Domènech E, Echarri A, García-Planella E, Guerra I, Gisbert JP, López-Sanromán A; en representación de GETECCU. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. Gastroenterol Hepatol 2018;41:205-21. [PMID: 29357999 DOI: 10.1016/j.gastrohep.2017.11.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
59 Sales-Campos H, Basso PJ, Alves VB, Fonseca MT, Bonfá G, Nardini V, Cardoso CR. Classical and recent advances in the treatment of inflammatory bowel diseases. Braz J Med Biol Res. 2015;48:96-107. [PMID: 25466162 DOI: 10.1590/1414-431x20143774] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 7.1] [Reference Citation Analysis]
60 Hoentjen F, Seinen ML, Hanauer SB, de Boer NK, Rubin DT, Bouma G, Harrell LE, van Bodegraven AA. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:363-369. [PMID: 22605661 DOI: 10.1002/ibd.23021] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 9.0] [Reference Citation Analysis]
61 Varkas G, Ribbens C, Louis E, Van den Bosch F, Lories R, Vermeire S, Elewaut D, De Vos M. Expert consensus: practical algorithms for management of inflammatory bowel disease patients presenting with back pain or peripheral arthropathies. Aliment Pharmacol Ther 2019;50:1204-13. [PMID: 31650573 DOI: 10.1111/apt.15519] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
62 Levesque BG, Loftus EV. Initiating azathioprine for Crohn’s disease. Clin Gastroenterol Hepatol. 2012;10:460-465. [PMID: 22330233 DOI: 10.1016/j.cgh.2012.01.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
63 Giraud EL, Thomas PWA, van Lint JA, van Puijenbroek EP, Römkens TEH, West RL, Russel MGVM, Jansen JM, Jessurun NT, Hoentjen F; IBDREAM registry. Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry. Drug Saf 2021;44:581-8. [PMID: 33538994 DOI: 10.1007/s40264-021-01045-3] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
64 高树娟, 施瑞华. 炎症性肠病治疗的新进展. 世界华人消化杂志 2012; 20(36): 3742-3747 [DOI: 10.11569/wcjd.v20.i36.3742] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Calafat M, Mañosa M, Mesonero F, Guardiola J, Mínguez M, Nos P, Vera I, Taxonera C, Iglesias E, Ricart E, Gisbert JP, Calvet X, García-López S, Monfort D, Pérez Calle JL, Riestra S, Gomollón F, Garcia-Planella E, Bermejo F, Hernández V, Martín-Arranz MD, Gutiérrez A, Torres P, Cañete F, Domènech E; ENEIDA registry of GETECCU . Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry. J Crohns Colitis 2020;14:1290-8. [PMID: 32201893 DOI: 10.1093/ecco-jcc/jjaa055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
66 Calafat M, Mañosa M, Cañete F, Ricart E, Iglesias E, Calvo M, Rodríguez-Moranta F, Taxonera C, Nos P, Mesonero F, Martín-Arranz MD, Mínguez M, Gisbert JP, García-López S, de Francisco R, Gomollón F, Calvet X, Garcia-Planella E, Rivero M, Martínez-Cadilla J, Argüelles F, Arias L, Cimavilla M, Zabana Y, Domènech E; ENEIDA registry of GETECCU. Increased risk of thiopurine-related adverse events in elderly patients with IBD. Aliment Pharmacol Ther 2019;50:780-8. [PMID: 31429097 DOI: 10.1111/apt.15458] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
67 Hübener S, Oo YH, Than NN, Hübener P, Weiler-normann C, Lohse AW, Schramm C. Efficacy of 6-Mercaptopurine as Second-Line Treatment for Patients With Autoimmune Hepatitis and Azathioprine Intolerance. Clinical Gastroenterology and Hepatology 2016;14:445-53. [DOI: 10.1016/j.cgh.2015.09.037] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]